Meeting Planned By FDA On Collecting Subgroup Data For Product Submissions
This article was originally published in The Gray Sheet
The agency plans a public meeting, required by the FDA Safety and Innovation Act, to chart progress on its action plan to improve industry data collection on demographic subgroups for product submissions and labeling for Feb. 29 at its Maryland headquarters.
You may also be interested in...
FDA should more strongly enforce requirements for adequate demographic subgroup representation in clinical trials for devices and other medical products, participants said at an April 1 meeting on collection and analysis of clinical trial subpopulation data to support product registration.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.